Acoustic Neuroma (Vestibular Schwannoma) — Cost, Top Hospitals & Success Rates | MyMedicPlus

An acoustic neuroma — more precisely termed vestibular schwannoma — is a benign, slow-growing tumour arising from the Schwann cells that ensheath the vestibular branch of the vestibulocochlear nerve (cranial nerve VIII). It accounts for approximately 6–8% of all intracranial tumours and has an incidence of approximately 1–2 per 100,000 persons per year. The tumour originates in the internal auditory canal (IAC) and may extend into the cerebellopontine angle (CPA), where it can compress surrounding structures including the facial nerve (cranial nerve VII), the trigeminal nerve, the brainstem, and the cerebellum.

The vast majority (95%) of acoustic neuromas are unilateral and sporadic with no identified hereditary cause. Bilateral acoustic neuromas are the hallmark of neurofibromatosis type 2 (NF2), a rare autosomal dominant condition caused by mutations in the NF2 gene on chromosome 22. NF2-associated tumours tend to present earlier (second to third decade) and behave more aggressively than sporadic unilateral tumours.

Management options have expanded significantly over the past three decades. The three established approaches are: (1) active surveillance with serial MRI for small tumours in older patients or those with limited serviceable hearing, (2) microsurgical resection via retrosigmoid, translabyrinthine, or middle fossa approaches, and (3) stereotactic radiosurgery (single-fraction Gamma Knife or CyberKnife) or fractionated stereotactic radiotherapy (FSR) for tumours up to approximately 3 cm. The choice between these modalities requires careful shared decision-making, considering tumour size, growth rate, patient age, baseline hearing, facial nerve function, and patient preference.

Acoustic neuromas produce symptoms primarily through compression of adjacent cranial nerves and, in larger tumours, the brainstem. The characteristic symptom triad — unilateral sensorineural hearing loss, tinnitus, and vestibular dysfunction — reflects involvement of the cochlear and vestibular divisions of the eighth cranial nerve.

Unilateral sensorineural hearing loss is the presenting symptom in 90% of patients, typically progressive and asymmetric. High-frequency hearing loss is most common, though any audiometric pattern can occur. Sudden sensorineural hearing loss — an acute drop in hearing threshold — presents in 10–15% of cases and may be the first symptom. Tinnitus occurs in 70% of patients and is typically unilateral, matching the affected side. It is usually high-pitched and continuous, and may persist after treatment even if hearing is preserved.

Vestibular symptoms — imbalance, unsteadiness, and occasionally frank vertigo — affect 50–60% of patients. Unlike Ménière's disease, acute rotational vertigo attacks are uncommon; patients more typically describe chronic imbalance and difficulty in dim lighting or on uneven surfaces. Facial nerve dysfunction (weakness, numbness, or altered taste) is uncommon at presentation but occurs in larger tumours compressing the adjacent facial nerve in the IAC or CPA.

Large tumours (>3 cm) extending into the posterior fossa may cause trigeminal neuralgia, ipsilateral cerebellar ataxia, nystagmus, dysarthria, and ultimately hydrocephalus from compression of the fourth ventricle — though this late presentation is now rare with modern diagnostic awareness. Diagnosis is confirmed by gadolinium-enhanced MRI of the internal auditory canals and posterior fossa, which demonstrates the characteristic enhancement of the tumour. Audiological assessment (pure tone audiometry, speech discrimination scores, ABR — auditory brainstem response) completes the baseline evaluation.

Treatment selection is individualized based on tumour size and growth rate, patient age and life expectancy, baseline hearing status (serviceable vs. non-serviceable hearing), facial nerve function, and patient preference after thorough counselling.

Active surveillance (watch and wait) with serial gadolinium-enhanced MRI every 6–12 months is appropriate for: elderly patients (>70 years) with small tumours (<1.5 cm) and comorbidities that increase surgical risk; patients with small, non-growing tumours on initial imaging; patients with unilateral acoustic neuroma and good serviceable hearing where treatment risks losing that hearing; and patients with significant anaesthetic risk. Approximately 30–50% of tumours managed with surveillance show no growth over 5 years.

Microsurgical resection is preferred for: large tumours (>3 cm) causing brainstem compression or hydrocephalus; tumours with documented significant growth on serial MRI (>2 mm/year); patients with non-serviceable hearing in the affected ear who prefer definitive surgical cure; younger patients in good health where long-term tumour control is paramount; and patients with acute complications (facial nerve dysfunction, hydrocephalus). Surgical approach depends on tumour size and hearing status: retrosigmoid approach (best for large CPA tumours with hearing preservation potential), translabyrinthine approach (sacrifices hearing, good for any-size tumour, widely used), middle fossa approach (best for intracanalicular tumours in patients with serviceable hearing).

Stereotactic radiosurgery (SRS) with Gamma Knife or CyberKnife is appropriate for: tumours <3 cm in maximum diameter; patients with serviceable hearing where surgical risk to hearing is deemed unacceptable; elderly or medically unfit patients; and patients preferring a single-day outpatient procedure. SRS is contraindicated for large tumours compressing the brainstem or causing hydrocephalus, and for patients with NF2 who have already received significant radiation to adjacent structures.

Microsurgical resection aims for gross total resection (GTR) while preserving facial nerve continuity and, where possible, cochlear nerve function. The translabyrinthine approach sacrifices the labyrinth and cochlea, yielding no possibility of hearing preservation but providing the widest exposure with the lowest risk of facial nerve injury — it is the most commonly used approach in the USA and UK. The retrosigmoid (suboccipital) approach accesses the CPA without destroying the labyrinth, offering hearing preservation in 25–50% of patients with preoperative serviceable hearing. The middle fossa approach via a temporal craniotomy is used for small intracanalicular tumours with good hearing, achieving hearing preservation in 50–70% of appropriately selected cases.

Facial nerve monitoring with continuous intraoperative electromyography (EMG) is mandatory in all acoustic neuroma surgery, reducing permanent facial nerve paralysis rates. Modern series from high-volume skull base centres report immediate facial nerve function preservation (House-Brackmann Grade I–II) in 70–90% of patients after GTR. Neuronavigation systems and intraoperative ultrasound or endoscopy augment surgical precision.

Stereotactic radiosurgery (Gamma Knife): Leksell Gamma Knife delivers a precisely focused, single high-dose (typically 12–13 Gy) of convergent radiation beams to the tumour, sparing surrounding structures. The procedure takes 1–2 hours and is performed as an outpatient. Tumour control rates (no further growth) at 5 years are 90–97% for tumours ≤3 cm. Hearing preservation occurs in 60–70% of patients with serviceable preoperative hearing at 5 years. CyberKnife delivers fractionated radiosurgery over 3–5 sessions, achieving similar tumour control with potentially lower radiation dose per fraction.

Fractionated stereotactic radiotherapy (FSR): Uses 25–30 small daily fractions of radiation over 5–6 weeks. Preferred for larger tumours near critical structures where single-fraction radiosurgery would risk higher complication rates. Tumour control rates are comparable to single-fraction SRS at 5–10 years.

The prognosis for acoustic neuroma is generally excellent regardless of treatment modality chosen, as these are benign tumours. The primary goals of treatment are tumour control (preventing growth and compression of critical structures), preservation of facial nerve function, and maximising quality of life.

Microsurgical resection: Gross total resection is achieved in 85–95% of cases in experienced skull base centres, with recurrence rates of only 1–5% over 10 years after complete resection. The House-Brackmann grading system assesses facial nerve outcomes — the majority of patients at high-volume centres achieve Grade I (normal) or Grade II (slight weakness) facial nerve function after resection of large tumours. Hearing preservation with the retrosigmoid approach in patients with preoperative serviceable hearing ranges from 25% to 65% in published series, depending on tumour size and surgical experience.

Gamma Knife radiosurgery: Published series consistently demonstrate 90–97% tumour control rates at 5–10 years for tumours ≤3 cm. The CASCINA trial and multiple retrospective series show 50–60% of patients maintain serviceable hearing at 5 years after Gamma Knife compared to 0% hearing preservation with translabyrinthine surgery. Post-radiosurgery tumour volumes may initially increase (pseudoprogression) before stabilising — this imaging change should not be confused with treatment failure. Facial nerve function is preserved in >95% of patients after modern dose-reduced Gamma Knife protocols.

Active surveillance: In the 50–70% of patients whose tumours do not grow during the surveillance period, no intervention is needed and hearing loss is avoided. For patients in the 30–50% with documented growth, transition to radiosurgery or surgery remains effective.

Microsurgical resection carries the most significant risk profile. Facial nerve injury leading to paralysis or paresis is the most feared complication, occurring temporarily in 30–50% of patients and permanently (House-Brackmann Grade III–VI at one year) in 5–15% after large tumour resection even at high-volume centres. Permanent severe facial palsy causes significant functional disability (inability to close the eye, drooling, facial asymmetry) and psychological distress.

Hearing loss occurs in 100% of patients undergoing translabyrinthine resection and in 35–75% of patients undergoing hearing-preservation approaches, depending on tumour size and preoperative hearing level. Cerebrospinal fluid (CSF) leak occurs in 5–12% of patients, particularly with retrosigmoid approaches, and may require lumbar drain or surgical repair. Meningitis risk (bacterial or aseptic chemical meningitis from CSF exposure to blood products) occurs in 1–3%. Posterior fossa cerebellar hematoma or edema causes headache, ataxia, and in rare cases requires emergency decompression. Mortality at experienced centres is less than 0.5% for elective acoustic neuroma resection.

Radiosurgery complications: Post-radiosurgery facial nerve dysfunction occurs in 2–5% of patients, typically temporary numbness rather than palsy. Trigeminal neuropathy (facial numbness, pain) occurs in 3–8%. The cochlear nerve is most radiosensitive — progressive hearing loss after radiosurgery occurs at a rate of 3–5% per year; cumulative hearing deterioration affects 40–50% of patients at 10 years. Radiation-induced tumour transformation to malignancy is theoretically possible but has been reported in fewer than 20 cases worldwide and is considered exceptionally rare. Repeat radiosurgery for tumour recurrence carries higher complication rates.

After microsurgical resection, intensive care unit (ICU) monitoring for 24–48 hours is standard for posterior fossa surgery. Hospital discharge occurs at 4–7 days in uncomplicated cases. Audiological assessment and facial nerve function grading at 6 weeks, 3 months, and 6 months post-operatively tracks recovery. Vestibular rehabilitation physiotherapy is essential for managing post-operative balance dysfunction — a structured programme accelerates central compensation for the lost labyrinthine input.

MRI surveillance after surgery: For subtotal resection or near-total resection (preserving a small tumour remnant adjacent to the facial nerve), annual MRI for the first 5 years and then every 2–3 years detects early regrowth that may be addressed with radiosurgery before it becomes symptomatic. After gross total resection, MRI at 1 year, 3 years, and 5 years is standard at most centres.

After radiosurgery, tumour imaging with gadolinium MRI at 6 months, 12 months, and then annually is performed to confirm tumour control. Initial post-radiosurgery swelling (pseudoprogression) peaks at 6–12 months and typically resolves by 24 months — biopsy should not be performed for tumour swelling within 2 years of radiosurgery unless other features of failure are present.

Facial nerve rehabilitation: For patients with post-operative facial nerve paresis, a graded rehabilitation programme including facial physiotherapy, neuromuscular retraining, and — for non-recovering facial palsy — consideration of facial reanimation procedures (hypoglossal-facial nerve anastomosis, free muscle transfers, gold weight eyelid loading, or static slings) is coordinated through a facial nerve rehabilitation specialist. Psychological support for patients adjusting to permanent hearing loss and facial changes is an important component of comprehensive follow-up care.

Acoustic neuroma treatment costs vary enormously between countries and between surgical and radiosurgical approaches. In the United States, microsurgical resection at a major neurosurgical centre costs $80,000–$150,000 including surgeon fees, neurosurgeon and neuro-otologist fees, anaesthesia, intensive care, and hospitalisation. Gamma Knife radiosurgery at US centres costs $25,000–$60,000 for the single-session treatment including planning and equipment costs.

In India, leading skull base surgery centres such as Apollo Hospitals, Manipal Hospitals, Fortis, and CMC Vellore offer microsurgical acoustic neuroma resection with intraoperative neural monitoring at $8,000–$18,000 — a saving of 80–90% compared to US prices with equivalent surgical expertise and JCI accreditation at top centres. Gamma Knife radiosurgery in India costs $5,000–$12,000, compared to $25,000–$60,000 in the USA. Germany's university hospitals (Charité Berlin, LMU Munich) charge €15,000–€35,000 for surgical resection and €12,000–€20,000 for radiosurgery, with high standards of postoperative care. Thailand's Bumrungrad and Vejthani hospitals charge $12,000–$20,000 for surgical resection. Singapore's National University Hospital and Raffles Hospital charge SGD 20,000–50,000 for microsurgery. Mexico offers acoustic neuroma surgery at $10,000–$20,000 at private neurosurgical centres in Mexico City and Monterrey.

Radiosurgery centres with Leksell Gamma Knife units are available across Asia and Europe at 50–70% lower cost than the US, making this a strong medical tourism option for patients in whom radiosurgery is appropriate. Travel and accommodation costs are small relative to the treatment cost differential for patients from the USA or UK.

Active surveillance remains a widely used management strategy for small, non-growing tumours in older patients, deferring all intervention-related risks while maintaining the option for treatment if growth is documented. The observation vs. radiosurgery debate for small tumours is ongoing — meta-analyses suggest similar quality-of-life outcomes at 5 years between the two approaches, and patient preference after informed counselling is a key determinant.

Fractionated stereotactic radiotherapy (FSR) offers an alternative to single-session radiosurgery for medium-to-large tumours or those close to the brainstem, where fractionated lower daily doses may reduce complication rates. Proton beam therapy — charged particle radiation with the Bragg peak dosimetry advantage — is under investigation for acoustic neuromas, potentially offering even greater sparing of adjacent cochlear and brainstem structures than photon-based radiosurgery.

Beverley drug therapy: There is currently no approved pharmacological therapy for acoustic neuroma. Bevacizumab (anti-VEGF monoclonal antibody) has shown tumour volume reduction and hearing improvement in NF2-associated bilateral schwannomas in early-phase studies and is increasingly used as an off-label option for NF2 patients. For sporadic unilateral tumours, no systemic treatment is routinely recommended. Aspirin has been proposed as a potential growth-modifying agent based on retrospective observational data but lacks prospective trial evidence. Gene therapy and molecularly targeted approaches for NF2-mutation driven schwannomas are in preclinical development.